

UNCLASSIFIED

AD 259 464

*Reproduced
by the*

ARMED SERVICES TECHNICAL INFORMATION AGENCY
ARLINGTON HALL STATION
ARLINGTON 12, VIRGINIA



UNCLASSIFIED

NOTICE: When government or other drawings, specifications or other data are used for any purpose other than in connection with a definitely related government procurement operation, the U. S. Government thereby incurs no responsibility, nor any obligation whatsoever; and the fact that the Government may have formulated, furnished, or in any way supplied the said drawings, specifications, or other data is not to be regarded by implication or otherwise as in any manner licensing the holder or any other person or corporation, or conveying any rights or permission to manufacture, use or sell any patented invention that may in any way be related thereto.

259464

61-3-6
XEROX

397300

AD No. _____
ASTIA FILE COPY

HAZLETON LABORATORIES

INCORPORATED

Falls Church, Virginia

July 10, 1961

PROGRESS REPORT

No. 13

Contract No. DA 18-108-405-CML-826

FILE COPY
Return to
ASTIA
Arlington Hall Station
Arlington 12, Virginia
Attn: TISS

ASTIA
JUL 17 1961
RECEIVED
TIPDR

1110

I. Basic Screening Program

A. Compounds Screened - June

Compound Symbol	Dose Range		CAR*	SPE*	VDT*
	Cat	Dog			
CS 473	x	x			
CS 673	x	x		x	
CS 810	x	x			
CS 2247	x	x			
CS 2315	x	x		x	
CS 4297					x
CS 4297					x
CS 4297					x
CS 5394		x			
CS 6054	x	x			
CS 11455	x	x			
CS 11533			x		x
CS 11586			x		x
CS 11588	x		x		x
CS 11708				x	x
CS 11714	x		x		x
CS 11839					x
CS 12113	x	x			x
CS 12137	x	x			x
CS 12243		x			
CS 12406	x	x		x	x
CS 12587			x	x	
CS 12605	x	x		x	x
CS 12617	x	x		x	
CS 13463		x			
CS 13597			x	x	
CS 13598			x	x	
CS 14124				x	
CS 14630	x	x			
CS 15670	x	x		x	
EA 2387	x	x			
EA 2408	x	x			
Total	18	19	7	11	13

* CAR = Conditioned Avoidance Response SPE = Sustained
Physical Exercise VDT = Visual Discrimination Test

B. Compounds To Be Screened - July

Compound Symbol	Dose Range		CAR*	SPE*	VDT*
	Cat	Dog			
CS 473			x		
CS 673			x		x
CS 810			x		
CS 2247			x		
CS 2315			x		x
CS 5394	 x			x	
CS 6054			x	x	x
CS 10795			x		
CS 11455			x		x
CS 11708			x		
CS 11839			x	x	
CS 12113			x		
CS 12137			x		
CS 12243	 x				
CS 12406			x		
CS 12475			x	x	x
CS 12587					x
CS 12605			x		
CS 12617			x		x
CS 12833	 x	x			
CS 13389	 x	x			
CS 13390	 x	x			
CS 13463	 x			x	
CS 13466	 x	x			
CS 13597					x
CS 13598					x
CS 13599			x	x	x
CS 14124			x		x
CS 14127	 x	x			
CS 14630				x	x
CS 14633	 x	x			
(powder)					
CS 14633	 x	x			
(liquid)					
CS 15670			x		x
CS 16567	 x	x			
CS 16574			x	x	x
CS 18275	 x	x			
CS 19172	 x	x			
CS 19628	 x	x			
EA 2387				x	x
EA 2408				x	
Total		14** 11**	15	15	15

* CAR = Conditioned Avoidance Response SPE = Sustained Physical Exercise VDT = Visual Discrimination Test

** Additional compounds to be supplied by Army Chemical Center

II. Skin Penetration Testing Program

A. Completed

Submitted is a progress report of the work completed to date in standardizing the test procedure including a table of the results obtained from positive controls.

B. Projected

Skin screening of the 50 compounds listed in Report Group No. 10 are to be completed and reported.

III. Preclinical Pharmacology Program

A. Completed and submitted in This Report Group

1. Preclinical pharmacology studies of CS 12602 in rats and dogs.
2. Dose regression study of CS 12602 in dogs.
3. Dose regression study of EA 2277 in monkeys.

B. In Progress

1. Report preparation of preclinical pharmacology studies of EA 2233 and EA 2255 in rats and dogs.
2. Preclinical pharmacology studies of EA 1476 in rats and dogs.
3. Dose regression study of CS 12602 in monkeys.
4. Dose regression studies of EA 1476, EA 2233, and EA 2255 in dogs.

C. Projected

1. Dose regression studies of EA 1476, EA 2233, and EA 2255 in monkeys.
2. Preclinical pharmacology studies on two new compounds to be supplied by the Army Chemical Center.

IV. Additional Effort Requirements

A. Completed

Final comprehensive reports on those 29 compounds which were found to be of interest between January 1 and March 31, 1961, were completed and are submitted separately to the Army Chemical Center.

B. In Progress

1. Comparative study of atropine with scopolamine in the VDT test in monkeys.
2. Further modification of the positive reinforcement procedure, in which a maximum time interval is set beyond which a correct response will not be rewarded.
3. Antagonism studies between CS 4297 and CS 12602 in the VDT test in monkeys.
4. A summary report of all tests completed to date on CS 12602.

C. Projected

1. Further primary screening of the following compounds which were found to be of interest: CS 7139, CS 7194, CS 7750, CS 8064, and CS 8545.
2. Completion of the positive reinforcement procedure on EA 2277 in monkeys.
3. A tolerance study on EA 2277 in the CAR test.
4. Dose regression studies on CS 4649, CS 12614, and CS 12615 in monkeys.